primeoglucosylcimifugin
activ
chromon
isol
saposhnikovia
root
report
variou
activ
anticonvuls
anticanc
antiinflammatori
properti
purpos
studi
evalu
effect
primeoglucosylcimifugin
acut
lung
injuri
ali
induc
lipopolysaccharid
mice
balbc
mice
receiv
intraperiton
inject
primeoglucosylcimifugin
h
intranas
instil
lipopolysaccharid
lp
concentr
tumor
necrosi
factor
tnf
interleukin
il
interleukin
il
bronchoalveolar
lavag
fluid
balf
measur
enzymelink
immunosorb
assay
elisa
pulmonari
histolog
chang
evalu
hematoxylineosin
myeloperoxidas
mpo
activ
lung
tissu
lung
wetdri
weight
ratio
observ
furthermor
mitogenactiv
protein
kinas
mapk
signal
pathway
activ
phosphoryl
protein
determin
western
blot
analysi
primeoglucosylcimifugin
show
promis
antiinflammatori
effect
inhibit
activ
mapk
signal
pathway
acut
respiratori
distress
syndrom
ard
clinic
import
complic
sever
acut
lung
injuri
ali
human
highli
associ
sepsi
pneumonia
sever
acut
respiratori
syndrom
sar
signific
caus
morbid
mortal
critic
ill
patient
inflammatori
stimuli
microbi
pathogen
endotoxin
lipopolysaccharid
lp
well
recogn
abil
induc
pulmonari
inflamm
experiment
administr
lp
use
induc
pulmonari
inflamm
anim
model
ali
develop
ali
model
way
lp
instil
well
suit
preliminari
pharmacolog
studi
new
drug
therapeut
agent
instil
lp
mice
produc
control
ali
without
caus
system
inflamm
multiorgan
failur
lpsinduc
ali
consid
neutrophildepend
ali
contribut
local
recruit
activ
neutrophil
releas
proinflammatori
cytokin
tumor
necrosi
factor
tnf
interleukin
il
format
reactiv
oxygen
nitrogen
speci
neutrophil
recruit
lung
regard
histolog
hallmark
progress
ali
sever
candid
therapi
strategi
fluid
manag
surfact
glucocorticoid
stem
cell
appli
treat
acut
lung
injuri
acut
respiratori
distress
syndrom
last
decad
howev
mortal
result
condit
remain
high
fangfeng
root
saposhnikovia
divaricata
turcz
schischk
wide
appli
headach
febril
vertigo
arthralgia
import
member
tradit
chines
medicin
tcm
prove
numer
pharmacolog
effect
extract
fangfeng
suppress
adjuv
arthriti
inhibitori
effect
peptic
ulcer
analges
anticonvuls
anticanc
antiinflammatori
anticoagul
activ
etc
modern
pharmacolog
experi
abund
compound
isol
chromon
conmarin
polyacetylen
primeoglucosylcimifugin
major
activ
chromon
isol
fangfeng
recent
year
identifi
chromon
main
activ
compon
contribut
pharmacolog
efficaci
far
antiinflammatori
effect
primeoglucosylcimifugin
ali
yet
studi
therefor
mous
model
acut
lung
inflamm
present
studi
undertaken
examin
effect
primeoglucosylcimifugin
acut
lung
injuri
induc
intranas
instil
lp
balbc
mice
investig
possibl
mechan
primeoglucosylcimifugin
purchas
nation
institut
control
pharmaceut
biolog
product
jilin
china
fetal
bovin
serum
fb
dulbecco
modifi
eagl
medium
dmem
penicillin
streptomycin
cell
cultur
purchas
invitrogengibco
grand
island
ny
usa
bromid
mtt
dimethyl
sulfoxid
dmso
lipopolysaccharid
lp
escherichia
coli
purchas
sigma
chemic
co
san
diego
ca
usa
rabbit
polyclon
erk
mous
monoclon
phosphospecif
erk
antibodi
rabbit
polyclon
jnk
mous
monoclon
phosphospecif
jnk
antibodi
rabbit
polyclon
mous
monoclon
phosphospecif
antibodi
rabbit
mab
mous
mab
purchas
cell
signal
technolog
inc
beverli
hrpconjug
goat
antirabbit
goatmous
antibodi
provid
ge
healthcar
buckinghamshir
uk
mous
enzymelink
immunosorb
assay
elisa
kit
purchas
biolegend
ca
usa
myeloperoxidas
mpo
determin
kit
purchas
jiancheng
bioengin
institut
nanj
nanj
jiangsu
provinc
china
chemic
reagent
grade
balbc
male
mice
week
old
weigh
approxim
g
purchas
center
experiment
anim
baiqiuen
medic
colleg
jilin
univers
jilin
china
maintain
anim
facil
pathogen
free
condit
mice
fed
standard
diet
water
ad
libitum
hous
microisol
cage
standard
condit
temperatur
rel
humid
mice
allow
adapt
environ
day
experiment
anim
experi
perform
accord
nation
institut
health
nih
guid
care
use
laboratori
anim
approv
jilin
univers
anim
administr
committe
raw
mous
macrophag
cell
line
obtain
china
cell
line
bank
beij
china
cell
cultur
complet
medium
dmem
supplement
heatinactiv
fb
mm
glutamin
antibiot
uml
penicillin
uml
streptomycin
humidifi
incub
contain
co
air
cell
treat
variou
concentr
primeoglucosylcimifugin
h
follow
stimul
lp
mgl
cytotox
studi
induc
primeoglucosylcimifugin
evalu
mtt
assay
raw
macrophag
seed
plate
densiti
cellsml
complet
medium
incub
h
cell
treat
differ
concentr
primeoglucosylcimifugin
h
follow
stimul
lp
mgl
h
h
mtt
gl
ad
well
cell
incub
h
supernat
remov
cell
lyse
dmso
optic
densiti
measur
nm
micropl
reader
raw
cell
seed
plate
cellsml
treat
primeoglucosylcimifugin
h
prior
stimul
mgl
lp
h
co
incub
cellfre
supernat
collect
assay
concentr
supernat
raw
cell
cultur
measur
use
elisa
kit
accord
manufactur
instruct
biolegend
inc
camino
santa
fe
suit
e
san
diego
ca
usa
raw
cell
cellsml
plate
onto
plate
incub
h
treat
primeoglucosylcimifugin
h
stimul
mgl
lp
min
cell
collect
wash
three
time
icecold
pb
cell
treat
cell
lysi
buffer
mm
tri
ph
mm
nacl
mm
edta
ph
mm
mm
mm
phenylmethylsulfonyl
fluorid
mm
pnitrophenyl
phosphat
complet
mini
proteas
inhibitor
cocktail
boehring
mannheim
germani
kept
ice
min
cell
lysat
centrifug
g
min
obtain
cytosol
fraction
protein
concentr
determin
bca
protein
assay
kit
beyotim
haimen
china
aliquot
lysat
separ
sodium
dodecyl
sulfat
sd
polyacrylamid
gel
electrophoresi
page
electroblot
onto
polyvinyliden
difluorid
pvdf
membran
blot
block
wv
nonfat
dri
milk
h
follow
incub
specif
primari
antibodi
overnight
blot
wash
tween
salin
ttb
mm
trishcl
buffer
ph
contain
mm
nacl
volvol
tween
incub
peroxidaseconjug
secondari
antibodi
h
blot
wash
ttb
immunoact
protein
detect
use
ecl
plu
thermo
usa
mice
randomli
divid
five
group
control
group
lp
group
lp
primeoglucosylcimifugin
mgkg
bodyweight
primeoglucosylcimifugin
given
intraperiton
one
hour
later
lp
group
lp
primeoglucosylcimifugin
group
mice
given
lp
intranas
mgl
induc
acut
lung
injuri
control
mice
given
pb
intranas
without
lp
mice
aliv
h
lp
stimul
collect
balf
perform
three
time
tracheal
cannula
ml
autoclav
pb
instil
total
volum
ml
balf
centrifug
rpm
min
pellet
cell
concentr
balf
measur
use
sandwich
enzymelink
immunosorb
assay
elisa
kit
accord
protocol
recommend
manufactur
cell
pellet
resuspend
pb
total
cell
number
count
use
standard
hemocytomet
differ
cell
number
examin
count
smear
prepar
wrightgiemsa
stain
seven
hour
intranas
instil
lp
mous
lung
excis
immedi
weigh
obtain
wet
weight
dri
weight
determin
heat
lung
h
wd
ratio
calcul
divid
wet
weight
dri
weight
mpo
activ
reflect
parenchym
infiltr
neutrophil
macrophag
measur
describ
previous
mice
kill
h
lp
administr
diethyl
ether
anesthesia
lung
tissu
homogen
mm
hydroxyethyl
piperazin
ethanesulfon
acid
hepe
ph
contain
cetyltrimethyl
ammonium
bromid
ctab
subject
three
freezethaw
cycl
homogen
centrifug
min
cellfre
extract
store
use
mpo
activ
assay
use
mous
mpo
elisa
kit
sampl
dilut
phosphat
citrat
buffer
ph
histopatholog
examin
perform
mice
subject
balf
collect
lung
excis
fix
buffer
formalin
tissu
dehydr
grade
alcohol
embed
paraffin
slice
section
stain
hematoxylin
eosin
h
e
patholog
chang
lung
tissu
observ
light
microscop
valu
present
mean
sd
data
enter
databas
analyz
use
spss
softwar
spss
window
version
chicago
usa
comparison
group
made
oneway
anova
dunnett
ttest
student
ttest
pvalu
less
consid
statist
signific
assess
suitabl
concentr
primeoglucosylcimifugin
studi
raw
cell
incub
primeoglucosylcimifugin
concentr
rang
mgl
absenc
presenc
lp
cell
viabil
measur
mtt
test
h
later
result
show
primeoglucosylcimifugin
concentr
mgl
cytotox
effect
raw
cell
fig
concentr
cultur
supernat
raw
macrophag
measur
elisa
kit
fig
raw
macrophag
treat
lp
alon
produc
signific
amount
compar
control
group
howev
product
slightli
decreas
level
significantli
inhibit
dosedepend
manner
cell
treat
mgl
primeoglucosylcimifugin
p
b
p
b
contrast
concentr
significantli
increas
cell
treat
mgl
primeoglucosylcimifugin
p
b
order
investig
mechan
primeoglucosylcimifugin
inhibit
lpsinduc
cytokin
product
examin
level
lpsinduc
phosphoryl
jnk
mapk
cytoplasm
western
blot
analysi
use
three
differ
phosphorspeci
antibodi
studi
fig
show
lp
stimul
significantli
increas
phosphoryl
jnk
howev
primeoglucosylcimifugin
inhibit
phosphoryl
jnk
lpsinduc
cell
chang
express
nonphosphoryl
mapk
among
group
furthermor
examin
effect
primeoglucosylcimifugin
phosphoryl
degrad
result
show
lpsinduc
degrad
inhibit
pretreat
primeoglucosylcimifugin
dosedepend
manner
fig
balf
collect
h
lp
administr
cytokin
level
balf
measur
elisa
accord
manufactur
instruct
describ
materi
method
section
level
balf
increas
dramat
compar
control
group
fig
howev
pretreat
primeoglucosylcimifugin
mgkg
significantli
downregul
level
dosedepend
manner
p
b
p
b
seven
hour
lp
administr
balf
collect
evalu
total
cell
count
number
inflammatori
cell
balf
macrophag
neutrophil
shown
fig
lp
challeng
markedli
increas
number
total
cell
neutrophil
macrophag
compar
control
group
p
b
addit
pretreat
primeoglucosylcimifugin
found
significantli
decreas
number
total
cell
neutrophil
macrophag
p
b
p
b
evalu
lpsinduc
chang
pulmonari
vascular
permeabl
water
evalu
wet
weight
dri
weight
ratio
lung
lung
wd
ratio
evid
higher
h
lp
administr
compar
control
mice
illustr
p
b
pretreat
mice
primeoglucosylcimifugin
significantli
reduc
water
gain
fig
p
b
p
b
balf
collect
h
follow
lp
challeng
analyz
inflammatori
cytokin
fig
fig
fig
valu
present
mean
sem
n
group
p
b
vs
control
group
p
b
p
b
vs
lp
group
mpo
activ
fig
determin
assess
effect
primeoglucosylcimifugin
neutrophil
accumul
within
pulmonari
tissu
lp
challeng
result
significantli
increas
lung
mpo
activ
compar
control
group
p
b
howev
increas
reduc
primeoglucosylcimifugin
p
b
p
b
evalu
effect
primeoglucosylcimifugin
ali
observ
histolog
chang
primeoglucosylcimifugin
treatment
lpstreat
mice
lp
group
lung
significantli
damag
inflammatori
cell
infiltr
alveolar
wall
thicken
interstiti
edema
contrast
primeoglucosylcimifugin
mgkg
found
decreas
histopatholog
chang
fig
result
studi
indic
primeoglucosylcimifugin
promis
antiinflammatori
activ
treatment
primeoglucosylcimifugin
lp
challeng
attenu
lpsinduc
inflammatori
respons
raw
cell
significantli
protect
mice
lpsinduc
ali
studi
primarili
focus
antiinflammatori
effect
primeoglucosylcimifugin
lpsstimul
raw
cell
lp
glycolipid
constitut
major
portion
outermost
membran
gramneg
bacteria
bind
cell
membran
receptor
monocytesmacrophag
endotheli
cell
activ
signaltransduct
system
thu
result
synthesi
releas
cytokin
inflammatori
mediat
excess
product
proinflammatori
cytokin
enhanc
immun
respons
fight
invad
pathogen
also
deleteri
effect
like
perturb
regular
hemodynam
metabol
balanc
thu
import
target
treatment
inflammatori
diseas
inhibit
proinflammatori
mediat
shown
fig
level
proinflammatori
cytokin
downregul
level
upregul
primeoglucosylcimifugin
group
antiinflammatori
well
known
downregul
product
number
cytokin
combin
endotoxin
caus
express
induc
nitric
oxid
synthas
ino
macrophag
induc
no
import
pharmacolog
target
inflammatori
mutagenesi
research
prove
primeoglucosylcimifugin
inhibitori
effect
synthesi
induc
lp
raw
cell
combin
find
studi
seem
like
primeoglucosylcimifugin
inhibit
synthesi
produc
raw
cell
antiinflammatori
action
interfer
product
proinflammatori
cytokin
suppress
activ
preserv
express
protein
nfkb
key
transcript
factor
involv
regul
express
proinflammatori
mediat
includ
cytokin
chemokin
adhes
molecul
therebi
play
critic
role
mediat
inflammatori
respons
rest
condit
held
inact
howev
activ
stimul
variou
receptor
includ
tnf
receptor
tolllik
receptor
tlr
tcell
receptor
tcr
persist
activ
central
pathogenesi
mani
inflammatori
lung
disord
includ
chronic
obstruct
pulmonari
asthma
pneumonia
acut
lung
injuri
activ
implic
mapk
signal
pathway
inhibit
mapk
famili
pathway
erk
jnk
allevi
product
proinflammatori
cytokin
therefor
investig
possibl
primeoglucosylcimifugin
inhibit
product
via
interf
activ
mapk
result
show
primeoglucosylcimifugin
obvious
inhibit
activ
also
inhibit
lpsinduc
phosphoryl
jnk
raw
cell
fig
base
observ
result
suggest
primeoglucosylcimifugin
antiinflammatori
abil
suppress
express
proinflammatori
cytokin
block
activ
mapk
pathway
vitro
acut
lung
injuri
character
system
airway
inflammatori
respons
includ
cytokin
eg
chemokin
proinflammatori
mediat
varieti
cell
regul
migrat
pulmonari
infiltr
neutrophil
interstiti
tissu
neutrophil
import
compon
inflammatori
respons
character
acut
lung
injuri
ali
inflammatori
respons
initi
neutrophil
first
cell
recruit
site
infect
injuri
although
neutrophil
benefici
action
erad
microbi
infect
excess
neutrophil
activ
result
releas
cytokin
proinflammatori
mediat
result
tissu
injuri
contribut
develop
organ
dysfunct
ali
high
level
proinflammatori
cytokin
perform
central
role
initi
propag
inflammatori
cascad
lpsinduc
ali
cytokin
secret
alveolar
macrophag
stimul
chemotaxi
attract
neutrophil
injur
lung
studi
level
balf
lower
primeoglucosylcimifugin
group
lp
group
reduct
may
contribut
decreas
neutrophil
count
balf
lpsinduc
ali
model
treat
primeoglucosylcimifugin
edema
typic
symptom
inflamm
system
inflamm
local
inflamm
permeabl
edema
accompani
acut
lung
injuri
sever
pneumonia
acut
respiratori
distress
syndrom
ard
associ
alveolar
fluid
clearanc
capac
reduct
increas
capillari
endotheli
permeabl
alveolar
epitheli
barrier
disrupt
quantifi
magnitud
pulmonari
edema
determin
wd
ratio
lung
tissu
primeoglucosylcimifugin
shown
inhibit
ratio
hand
mpo
enzym
locat
mainli
primari
granul
neutrophil
thu
mpo
activ
parenchyma
reflect
adhes
margin
neutrophil
lung
lpsinduc
ali
model
larg
amount
pmn
recruit
peripher
blood
lung
produc
substanti
amount
mpo
reactiv
oxygen
deriv
final
result
cascadelik
respons
tissu
damag
contrast
administr
primeoglucosylcimifugin
markedli
suppress
lpsinduc
balf
neutrophilia
fig
mpo
activ
fig
well
amelior
histopatholog
chang
lung
tissu
produc
lp
challeng
fig
recent
studi
conduct
pravastatin
ceftiofur
pinocembrin
show
regulatori
effect
primeoglucosylcimifugin
suggest
agent
may
import
regul
inflammatori
respons
taken
togeth
result
indic
protect
effect
primeoglucosylcimifugin
acut
lung
injuri
mous
model
induc
lp
may
due
inhibit
inflammatori
mediat
limit
inflammatori
respons
lung
conclus
find
studi
show
primeoglucosylcimifugin
promis
antiinflammatori
effect
protect
effect
lpsinduc
ali
pretreat
primeoglucosylcimifugin
inhibit
releas
vitro
vivo
inflammatori
respons
counteract
mapk
activ
find
strongli
suggest
primeoglucosylcimifugin
potent
antiinflammatori
activ
may
repres
novel
strategi
modul
inflammatori
respons
studi
warrant
investig
clinic
use
primeoglucosylcimifugin
